The sexual effects of testosterone replacement in depressed men: Randomized, placebo-controlled clinical trial

Journal of Sex and Marital Therapy

Volumn 32, Issue 3, 2006, Pages 267-273

  Seidman, Stuart N ^a   Roose, Steven P ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERECTILE DYSFUNCTION; HAMILTON ANXIETY SCALE; HIGH RISK PATIENT; HUMAN; HYPOGONADISM; MAJOR DEPRESSION; MALE; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; SEXUAL FUNCTION; SEXUAL SATISFACTION; SEXUALITY; TREATMENT OUTCOME;

ADULT; AGED; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HORMONE REPLACEMENT THERAPY; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PERSONAL SATISFACTION; SEVERITY OF ILLNESS INDEX; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33646516876     PISSN: 0092623X     EISSN: 15210715     Source Type: Journal    
DOI: 10.1080/00926230600575355     Document Type: Article

References (18)

1. Anderson, R. A., Bancroft, J., & Wu, F. C. (1992). The effects of exogenous testosterone on sexuality and mood of normal men. Journal of Clinical Endocrinology and Metabolism, 75, 1503-1507.
2. Burris, A. S., Banks, S. M., Carter, C. S., Davidson, J. M., & Sherins, R. J. (1992). A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. Journal of Andrology, 13, 297-304.
3. Derogatis, L. R. (1997). The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report. Journal of Sex & Marital Therapy, 23, 291-304.
4. Derogatis, L. R., & Laban, M. P. (1998). Psychological assessment measures of human sexual functioning in clinical trials. International Journal of Imposence Research, 10(Suppl. 2), S13-S20.
5. First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1995). Structured Clinical Interview for DSM IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2:0). New York: Biometrics Research Department, New York State Psychiatric Institute.
6. Gray, A., Berlin, J. A., McKinlay, J. B., & Longcope, C. (1991). An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. Journal of Clinical Epidemiology, 7, 671-684.
7. Heuser, I. (1998). Testosterone, gonadotropin and cortisol secretion in male patients with major depression. The International Journal of Neuropsychopharmacology, 1, 19.
8. Luisi, M., & Franchi, F. (1980). Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. Journal of Endocrinological Investigation, 3, 305-308.
9. McNicholas, T. A., Dean, J. D., Mulder, H., Carnegie, C., & Jones, N. A. (2003). A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU International, 91, 69-74.
10. Plymate, S. (1994). Hypogonadism. Endocrinology and Metabolism Clinics of North America, 23, 749-772.
11. Rupprecht, R., Rupprecht, C., Rupprecht, M., Noder, M., & Schwarz, W. (1988). Different reactivity of the hypothalamo-pituitary-gonadal-axis in depression and normal controls. Pharmacopsychiatry, 21, 438-439.
12. Seidman, S. N. (2005). Neuroendocrinology of mood disorders. In D. J. Stein, A. F. Schatzberg, & D. J. Kupfer (Eds.), Textbook of mood disorders (1st ed.) (pp. 117-130). Washington, DC: American Psychiatric Press.
13. Seidman, S. N., Roose, S. P., & Rosen, R. C. (2004). Sexual dysfunction and pharmacological treatments: Biological interactions. In D. S. Charney & E. Nestler (Eds.), Neurobiology of mental illness (2nd ed.) (pp. 1086-1100). New York: Oxford.
14. Seidman, S. N., Spatz, E., Rizzo, C., & Roose, S. P. (2001). Testosterone replacement therapy for hypogonadal men with major depressive disorder: A randomized, placebo-controlled clinical trial. Journal of Clinical Psychiatry, 62, 406-412.
15. Steidle, C., Schwartz, S., Jacoby, K., Sebree, T., Smith, T., & Bachand, R. (2003). AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology & Metabolism, 88, 2673-2681.
16. Steiger, A., von Bardeleben, U., Guldner, J., Lauer, C., Rothe, B., & Holsboer, F. (1993). The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs. Biological Psychiatry, 17, 125-137.
17. Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J. et al. (2004). Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. Journal of Clinical Endocrinology & Metabolism, 89, 2085-2098.
18. Wang, C., Swerdloff, R. S., Iranmanesh, A., Dobs, A., Snyder, P. J., Cunningham, G. et al. (2000). Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. Journal of Clinical Endocrinology & Metabolism, 85, 2839-2853.